ImmunityBio, Inc.

IBRX

US45256X1037

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 24/05/2024 am IST			5-day change	1st Jan Change
6.68 ^USD	-3.75%		-13.81%	+33.07%

09/05	ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
07/05	ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment	MT

Steve Gorlin Resigns from the Board of Directors of NantKwest, Inc

June 20, 2020 at 02:05 am IST

On June 16, 2020, Steve Gorlin resigned from the board of directors of NantKwest, Inc. effective immediately.

Latest news about ImmunityBio, Inc.

ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment	07/05	MT
ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®	07/05	CI
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline	06/05	MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline	03/05	MT
Immunitybio, Inc., Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin Across All Cancer Types	03/05	CI
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline	30/04	MT
Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating	29/04	MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	29/04	MT
Transcript : ImmunityBio, Inc. - Special Call	26/04
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer	25/04	CI
ImmunityBio Gaining in Tuesday Pre-Market after FDA Approval for Anktiva-Bacterium Combination for Bladder Cancer	23/04	MT
Upcoming Big Tech Earnings Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	23/04	MT
Top Premarket Gainers	23/04	MT
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva	23/04	DJ
US FDA approves ImmunityBio's bladder cancer therapy	23/04	RE
ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	23/04	CI
U.S. FDA approves ImmunityBio's bladder cancer therapy	23/04	RE
ImmunityBio Files Mixed Shelf	18/04	MT
North American Morning Briefing : Markets Steady -2-	26/03	DJ
Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating	25/03	MT
ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
North American Morning Briefing : Stock Futures -2-	19/03	DJ
ImmunityBio Announces Data from A Phase 1 Pilot Study	05/03	CI
ImmunityBio Says Cancer Vaccine Trial Moving to Controlled Phase	21/02	MT

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

Sector

Biotechnology & Medical Research

Calendar

31/05/2024 - American Society of Clinical Oncology Annual Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ImmunityBio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.94 USD

Average target price

7.5 USD

Spread / Average Target

+8.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNITYBIO, INC.	+33.07%	4.8B
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B

Bio Therapeutic Drugs

ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Biotechnology & Medical Research

Steve Gorlin Resigns from the Board of Directors of NantKwest, Inc

Latest news about ImmunityBio, Inc.

Chart ImmunityBio, Inc.

Company Profile

Income Statement Evolution

Ratings for ImmunityBio, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs